Dr. Karen Kelly describes her thought process on which molecular markers are those clearly indicated for  patients with advanced NSCLC, as well as whether smoking status factors into her approach.

[powerpress]

Dr. Lecia Sequist describes the state of the art and her view of current best practices on molecular testing for advanced non-small cell lung cancer.

[powerpress]